Provenienza dei contatti di primo grado di Raghu Kalluri
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Private Company | Pharmaceuticals: Major | 16 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Raghu Kalluri tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Biotechnology | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
| BIOGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Director/Board Member Director of Finance/CFO Corporate Officer/Principal | |
| IRONWOOD PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| AC IMMUNE SA | Pharmaceuticals: Major | Chairman | |
| GENOCEA BIOSCIENCES, INC. | Biotechnology | Director of Finance/CFO | |
| OVID THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Genesis Research & Development Corp. Ltd.
 Genesis Research & Development Corp. Ltd. Financial ConglomeratesFinance Genesis Research & Development Corp. Ltd. operates as a development stage company. Previously, it was a technology investment company that builds a broad therapeutic development platform targeting immune disorders and cancer and a novel single stranded gene silencing technology using the RNAi mechanism. The company was founded by James Douglas Watson in 1994 and is headquartered in Auckland, New Zealand. | Financial Conglomerates | Director/Board Member Corporate Officer/Principal | |
| BLUEBIRD BIO, INC. | Biotechnology | Director/Board Member Director of Finance/CFO | |
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Chief Executive Officer Private Equity Investor Private Equity Investor Private Equity Investor | |
| McGill University | College/University | Undergraduate Degree Doctorate Degree | |
| INFINITY PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| Massachusetts Institute of Technology | College/University | Founder Corporate Officer/Principal Director/Board Member Undergraduate Degree Undergraduate Degree | |
| University of Durham | College/University | Undergraduate Degree | |
| London Business School | College/University | Masters Business Admin | |
Odyssey Partners Ltd.
 Odyssey Partners Ltd. Investment ManagersFinance Odyssey Partners Ltd. (OPL) is an independent private equity investment firm located in London. Established in 2000 by Julian Fellerman and Richard Kleiner, OPL is the investment adviser of Avanti Capital Plc. (LSE: AVA), a UK-based private equity firm. | Investment Managers | Corporate Officer/Principal | |
LS Dissolution, Inc.
 LS Dissolution, Inc. Chemicals: Major DiversifiedProcess Industries LS Dissolution, Inc. engages in the production of petroleum replacement products and industrial chemicals. It offers chemical and fuel products. The company was founded by George M. Church, Christopher Somerville, Noubar B. Afeyan and Jay D. Keasling in 2005 and is headquartered in South San Francisco, CA. | Chemicals: Major Diversified | Director/Board Member Founder | |
| REGULUS THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member | |
| Armenian General Benevolent Union | Director/Board Member | ||
| University of Massachusetts Lowell | College/University | Undergraduate Degree | |
Midori USA, Inc.
 Midori USA, Inc. Miscellaneous Commercial ServicesCommercial Services Midori USA, Inc. develops cellulosic technology for conversion of biomass to fuels. It offers biomass barrier technology that melts and digests biomass into sugars with a solid, recyclable catalyst. The company was founded by J. M. Geremia and Brian Baynes in 2008 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Director/Board Member | |
| AXCA HEALPAR | Biotechnology | Director/Board Member Founder | |
Xenikos BV
 Xenikos BV Medical SpecialtiesHealth Technology Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands. | Medical Specialties | Chairman | |
| IDEA Foundation | Director/Board Member | ||
Just - Evotec Biologics, Inc.
 Just - Evotec Biologics, Inc. Specialty StoresRetail Trade Just Biotherapeutics, Inc. operates as biotechnology firm. Its products include biosimilars and novel and repositioned biologics. The firm also offers molecular design, process and product platform and manufacturing and plant design services. The company was founded by James N. Thomas, Victor P. Fung, Dean K. Pettit, and Yining Zhao in 2014 and is headquartered in Seattle, WA. | Specialty Stores | Director/Board Member Director/Board Member | |
| ARVINAS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| EVELO BIOSCIENCES, INC. | Pharmaceuticals: Major | Founder Director of Finance/CFO | |
| RUBIUS THERAPEUTICS | Biotechnology | Founder Founder | |
| KALEIDO BIOSCIENCES, INC. | Pharmaceuticals: Major | Founder | |
| VBI VACCINES INC. | Biotechnology | Chairman Director/Board Member | |
CiBO Technologies, Inc.
 CiBO Technologies, Inc. Packaged SoftwareTechnology Services CiBO Technologies, Inc. is a science-driven software company which engage sin the modelling and simulation of agricultural ecosystems. The firm offers CIBO and CIBO Plus software products. The company was founded by Ignacio Bemposta Martinez and Bruno Basso in 2015 and is headquartered in Cambridge, MA. | Packaged Software | Director/Board Member | |
Ohana Biosciences, Inc.
 Ohana Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ohana Biosciences, Inc. operates early stage biotechnology firm. The company is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Director/Board Member | |
Cygnal Therapeutics, Inc.
 Cygnal Therapeutics, Inc. BiotechnologyHealth Technology Cygnal Therapeutics, Inc. develops drugs for cancer, immunological diseases and regenerative processes. The company was founded by Noubar Afeyan, Avak Kahvejian and Jordi Mata-Fink in 2017 and is headquartered in Cambridge, MA. | Biotechnology | Founder Director/Board Member Founder | |
| SANA BIOTECHNOLOGY, INC. | Biotechnology | Founder Chief Tech/Sci/R&D Officer | |
Ring Therapeutics, Inc.
 Ring Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ring Therapeutics, Inc. engages in the development of a gene therapy platform. Its Anellovector platform provides tissue specifities benefitting from the inherent diversity of tropism afforded by the commensal virome. The company was founded in 2000 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Founder Chief Tech/Sci/R&D Officer | |
Cellarity Inc.
 Cellarity Inc. BiotechnologyHealth Technology Cellarity Inc. engages in the operation of platform to design medicines targeting the full cellular and molecular complexity of disease. The company was founded by Avak Kahvejian, James J. Collins, Noubar Afeyan, and Nicholas Plugis in 2017 and is headquartered in Cambridge, MA. | Biotechnology | Founder Founder | |
Tessera Therapeutics, Inc.
 Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | Biotechnology | Founder | |
Hemab ApS
 Hemab ApS BiotechnologyHealth Technology Hemab ApS develops antibodies for the treatment of rare bleeding disorders. The company is based in Copenhagen, Denmark. The Danish company was founded in 2019 by Johan Henrik Faber. Benny Sorensen has been the CEO of the company since 2020. | Biotechnology | Director/Board Member Chief Executive Officer | |
Generate Biomedicines, Inc.
 Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | Biotechnology | Founder Founder | |
Cytoimmune Therapeutics, Inc.
 Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | Biotechnology | Director/Board Member | |
| PANACEA ACQUISITION CORP. II | Financial Conglomerates | Director/Board Member | |
Stablix, Inc.
 Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | Miscellaneous Commercial Services | Director/Board Member | |
Profound Therapeutics
 Profound Therapeutics Pharmaceuticals: OtherHealth Technology Profound Therapeutics is a company that is focused on discovering new medicines by expanding the human proteome. The company is based in Cambridge, MA. The company uses their platform, Profoundry, to identify and validate proteins and understand their therapeutic potential. This results in a growing database of novel proteins and their roles in health and disease. The company was founded in 2020 by Avak Kahvejian, who has been the CEO since then. | Pharmaceuticals: Other | Chairman Chief Executive Officer | |
Ampersand Biomedicines
 Ampersand Biomedicines BiotechnologyHealth Technology Ampersand Biomedicines is an American company that designs programmable medicines that work precisely where needed in the body and nowhere else. The company's computationally powered platform identifies ideal addresses for drug localization and informs the design of and-body™ therapeutics that have the optimal therapeutic effect. The result is smarter biologic medicines that target the site of disease without affecting healthy tissue or cells. Ampersand is enabling potent mechanisms to treat disease by creating and programming therapeutics that are more efficacious, without compromising on safety or tolerability. The company was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering. Jason Gardner has been the CEO of the company since 2023. | Biotechnology | Founder Founder |
Statistiche
Distribuzione geografica
| Stati Uniti | 40 |
| Regno Unito | 6 |
| Svizzera | 2 |
| Nuova-Zelanda | 2 |
| Canada | 2 |
Settori
| Health Technology | 28 |
| Finance | 8 |
| Commercial Services | 7 |
| Consumer Services | 5 |
| Distribution Services | 2 |
Posizioni
| Director/Board Member | 181 |
| Founder | 62 |
| Independent Dir/Board Member | 51 |
| Corporate Officer/Principal | 51 |
| Chairman | 50 |
Contatti più connessi
| Insiders | |
|---|---|
| Noubar Afeyan | 76 |
| Steven Gillis | 58 |
| Charles Cooney | 37 |
| Briggs Morrison | 26 |
| Douglas Williams | 25 |
| Eric S. Lander | 15 |
| Linda Bain | 15 |
| Avak Kahvejian | 13 |
| Richard Brudnick | 13 |
| Phillip Samayoa | 11 |
| Jonathan Michael Poole | 9 |
| Karen Bernstein | 9 |
| Konstantin Konstantinov | 8 |
| Benny Sorensen | 5 |
| Sriram Sathyanarayanan | 3 |
- Borsa valori
- Insiders
- Raghu Kalluri
- Connessioni Società
